Which has stronger valuation & earnings, BBIO or ARGX?

argenex has higher revenue and earnings than BridgeBio Pharma. BridgeBio Pharma is trading at a lower price-to-earnings ratio than argenex, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio BridgeBio Pharma $502.08M 32.41 -$724.93M -$3.74 N/A argenex $4.25B 12.83 $1.29B $22.46 39.01

Does the media favor BBIO or ARGX?

In the previous week, BridgeBio Pharma had 13 more articles in the media than argenex. MarketBeat recorded 18 mentions for BridgeBio Pharma and 5 mentions for argenex. BridgeBio Pharma's average media sentiment score of 0.70 beat argenex's score of 0.65 indicating that BridgeBio Pharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BridgeBio Pharma 6 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive argenex 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts prefer BBIO or TAK?

BridgeBio Pharma currently has a consensus target price of $94.63, suggesting a potential upside of 13.90%. Given BridgeBio Pharma's stronger consensus rating and higher probable upside, analysts clearly believe BridgeBio Pharma is more favorable than Takeda Pharmaceutical. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score BridgeBio Pharma 1 Sell rating(s) 2 Hold rating(s) 20 Buy rating(s) 0 Strong Buy rating(s) 2.83 Takeda Pharmaceutical 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25

Does the media prefer BBIO or TAK?

In the previous week, BridgeBio Pharma had 17 more articles in the media than Takeda Pharmaceutical. MarketBeat recorded 18 mentions for BridgeBio Pharma and 1 mentions for Takeda Pharmaceutical. BridgeBio Pharma's average media sentiment score of 0.70 beat Takeda Pharmaceutical's score of -0.31 indicating that BridgeBio Pharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BridgeBio Pharma 6 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Takeda Pharmaceutical 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer BBIO or RVMD?

In the previous week, BridgeBio Pharma had 7 more articles in the media than Revolution Medicines. MarketBeat recorded 18 mentions for BridgeBio Pharma and 11 mentions for Revolution Medicines. BridgeBio Pharma's average media sentiment score of 0.70 beat Revolution Medicines' score of 0.63 indicating that BridgeBio Pharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BridgeBio Pharma 6 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Revolution Medicines 4 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer BBIO or ONC?

In the previous week, BridgeBio Pharma had 10 more articles in the media than BeOne Medicines. MarketBeat recorded 18 mentions for BridgeBio Pharma and 8 mentions for BeOne Medicines. BeOne Medicines' average media sentiment score of 0.77 beat BridgeBio Pharma's score of 0.70 indicating that BeOne Medicines is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BridgeBio Pharma 6 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive BeOne Medicines 3 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

BridgeBio Pharma (BBIO) Competitors

$83.08 -2.81 (-3.27%)

Closing price 07/13/2026 04:00 PM Eastern

Extended Trading

$82.42 -0.66 (-0.79%)

As of 07/13/2026 07:29 PM Eastern

Compare

BBIO vs. ARGX, TAK, RVMD, TEVA, and ONC

Should you buy BridgeBio Pharma stock or one of its competitors? MarketBeat compares BridgeBio Pharma with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with BridgeBio Pharma include argenex (ARGX), Takeda Pharmaceutical (TAK), Revolution Medicines (RVMD), Teva Pharmaceutical Industries (TEVA), and BeOne Medicines (ONC). These companies are all part of the "pharmaceutical products" industry.

How does BridgeBio Pharma compare to argenex?

BridgeBio Pharma (NASDAQ:BBIO) and argenex (NASDAQ:ARGX) are both large-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, institutional ownership, dividends, risk, profitability, analyst recommendations, valuation and media sentiment.

argenex has a net margin of 31.31% compared to BridgeBio Pharma's net margin of -124.42%. argenex's return on equity of 44.37% beat BridgeBio Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BridgeBio Pharma	-124.42%	N/A	-65.81%
argenex	31.31%	44.37%	37.55%

BridgeBio Pharma has a beta of 0.95, indicating that its share price is 5% less volatile than the broader market. Comparatively, argenex has a beta of 0.45, indicating that its share price is 55% less volatile than the broader market.

argenex has higher revenue and earnings than BridgeBio Pharma. BridgeBio Pharma is trading at a lower price-to-earnings ratio than argenex, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BridgeBio Pharma	$502.08M	32.41	-$724.93M	-$3.74	N/A
argenex	$4.25B	12.83	$1.29B	$22.46	39.01

BridgeBio Pharma currently has a consensus price target of $94.63, indicating a potential upside of 13.90%. argenex has a consensus price target of $1,037.61, indicating a potential upside of 18.41%. Given argenex's stronger consensus rating and higher possible upside, analysts clearly believe argenex is more favorable than BridgeBio Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BridgeBio Pharma	1 Sell rating(s)	2 Hold rating(s)	20 Buy rating(s)	0 Strong Buy rating(s)	2.83
argenex	0 Sell rating(s)	4 Hold rating(s)	18 Buy rating(s)	2 Strong Buy rating(s)	2.92

99.9% of BridgeBio Pharma shares are owned by institutional investors. Comparatively, 60.3% of argenex shares are owned by institutional investors. 14.2% of BridgeBio Pharma shares are owned by insiders. Comparatively, 2.4% of argenex shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

In the previous week, BridgeBio Pharma had 13 more articles in the media than argenex. MarketBeat recorded 18 mentions for BridgeBio Pharma and 5 mentions for argenex. BridgeBio Pharma's average media sentiment score of 0.70 beat argenex's score of 0.65 indicating that BridgeBio Pharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BridgeBio Pharma	6 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
argenex	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

argenex beats BridgeBio Pharma on 10 of the 17 factors compared between the two stocks.

How does BridgeBio Pharma compare to Takeda Pharmaceutical?

BridgeBio Pharma (NASDAQ:BBIO) and Takeda Pharmaceutical (NYSE:TAK) are both large-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, profitability, earnings, analyst recommendations, valuation, institutional ownership, media sentiment and risk.

Takeda Pharmaceutical has a net margin of 4.31% compared to BridgeBio Pharma's net margin of -124.42%. Takeda Pharmaceutical's return on equity of 11.20% beat BridgeBio Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BridgeBio Pharma	-124.42%	N/A	-65.81%
Takeda Pharmaceutical	4.31%	11.20%	5.48%

BridgeBio Pharma has a beta of 0.95, meaning that its share price is 5% less volatile than the broader market. Comparatively, Takeda Pharmaceutical has a beta of -0.07, meaning that its share price is 107% less volatile than the broader market.

BridgeBio Pharma currently has a consensus target price of $94.63, suggesting a potential upside of 13.90%. Given BridgeBio Pharma's stronger consensus rating and higher probable upside, analysts clearly believe BridgeBio Pharma is more favorable than Takeda Pharmaceutical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BridgeBio Pharma	1 Sell rating(s)	2 Hold rating(s)	20 Buy rating(s)	0 Strong Buy rating(s)	2.83
Takeda Pharmaceutical	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

99.9% of BridgeBio Pharma shares are owned by institutional investors. Comparatively, 9.2% of Takeda Pharmaceutical shares are owned by institutional investors. 14.2% of BridgeBio Pharma shares are owned by company insiders. Comparatively, 0.0% of Takeda Pharmaceutical shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

BridgeBio Pharma has higher earnings, but lower revenue than Takeda Pharmaceutical. BridgeBio Pharma is trading at a lower price-to-earnings ratio than Takeda Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BridgeBio Pharma	$502.08M	32.41	-$724.93M	-$3.74	N/A
Takeda Pharmaceutical	$28.32B	1.85	-$1.01B	$0.39	42.28

In the previous week, BridgeBio Pharma had 17 more articles in the media than Takeda Pharmaceutical. MarketBeat recorded 18 mentions for BridgeBio Pharma and 1 mentions for Takeda Pharmaceutical. BridgeBio Pharma's average media sentiment score of 0.70 beat Takeda Pharmaceutical's score of -0.31 indicating that BridgeBio Pharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BridgeBio Pharma	6 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Takeda Pharmaceutical	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

BridgeBio Pharma beats Takeda Pharmaceutical on 10 of the 16 factors compared between the two stocks.

How does BridgeBio Pharma compare to Revolution Medicines?

BridgeBio Pharma (NASDAQ:BBIO) and Revolution Medicines (NASDAQ:RVMD) are both large-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, media sentiment, earnings, analyst recommendations, dividends, institutional ownership, valuation and risk.

BridgeBio Pharma has a beta of 0.95, meaning that its stock price is 5% less volatile than the broader market. Comparatively, Revolution Medicines has a beta of 1.37, meaning that its stock price is 37% more volatile than the broader market.

99.9% of BridgeBio Pharma shares are held by institutional investors. Comparatively, 94.3% of Revolution Medicines shares are held by institutional investors. 14.2% of BridgeBio Pharma shares are held by insiders. Comparatively, 7.6% of Revolution Medicines shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

BridgeBio Pharma has higher revenue and earnings than Revolution Medicines. Revolution Medicines is trading at a lower price-to-earnings ratio than BridgeBio Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BridgeBio Pharma	$502.08M	32.41	-$724.93M	-$3.74	N/A
Revolution Medicines	$11.58M	3,377.18	-$1.13B	-$7.07	N/A

BridgeBio Pharma presently has a consensus price target of $94.63, suggesting a potential upside of 13.90%. Revolution Medicines has a consensus price target of $144.00, suggesting a potential downside of 21.72%. Given BridgeBio Pharma's higher probable upside, analysts plainly believe BridgeBio Pharma is more favorable than Revolution Medicines.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BridgeBio Pharma	1 Sell rating(s)	2 Hold rating(s)	20 Buy rating(s)	0 Strong Buy rating(s)	2.83
Revolution Medicines	1 Sell rating(s)	1 Hold rating(s)	18 Buy rating(s)	2 Strong Buy rating(s)	2.95

In the previous week, BridgeBio Pharma had 7 more articles in the media than Revolution Medicines. MarketBeat recorded 18 mentions for BridgeBio Pharma and 11 mentions for Revolution Medicines. BridgeBio Pharma's average media sentiment score of 0.70 beat Revolution Medicines' score of 0.63 indicating that BridgeBio Pharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BridgeBio Pharma	6 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Revolution Medicines	4 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Revolution Medicines has a net margin of 0.00% compared to BridgeBio Pharma's net margin of -124.42%. BridgeBio Pharma's return on equity of 0.00% beat Revolution Medicines' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BridgeBio Pharma	-124.42%	N/A	-65.81%
Revolution Medicines	N/A	-83.22%	-59.06%

Summary

BridgeBio Pharma beats Revolution Medicines on 11 of the 17 factors compared between the two stocks.

How does BridgeBio Pharma compare to Teva Pharmaceutical Industries?

BridgeBio Pharma (NASDAQ:BBIO) and Teva Pharmaceutical Industries (NYSE:TEVA) are both large-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, dividends, profitability, earnings, analyst recommendations, risk, institutional ownership and media sentiment.

BridgeBio Pharma has a beta of 0.95, meaning that its stock price is 5% less volatile than the broader market. Comparatively, Teva Pharmaceutical Industries has a beta of 0.86, meaning that its stock price is 14% less volatile than the broader market.

BridgeBio Pharma currently has a consensus target price of $94.63, suggesting a potential upside of 13.90%. Teva Pharmaceutical Industries has a consensus target price of $41.78, suggesting a potential upside of 29.94%. Given Teva Pharmaceutical Industries' higher possible upside, analysts plainly believe Teva Pharmaceutical Industries is more favorable than BridgeBio Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BridgeBio Pharma	1 Sell rating(s)	2 Hold rating(s)	20 Buy rating(s)	0 Strong Buy rating(s)	2.83
Teva Pharmaceutical Industries	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.80

99.9% of BridgeBio Pharma shares are held by institutional investors. Comparatively, 54.1% of Teva Pharmaceutical Industries shares are held by institutional investors. 14.2% of BridgeBio Pharma shares are held by company insiders. Comparatively, 0.5% of Teva Pharmaceutical Industries shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

In the previous week, Teva Pharmaceutical Industries had 3 more articles in the media than BridgeBio Pharma. MarketBeat recorded 21 mentions for Teva Pharmaceutical Industries and 18 mentions for BridgeBio Pharma. Teva Pharmaceutical Industries' average media sentiment score of 1.13 beat BridgeBio Pharma's score of 0.70 indicating that Teva Pharmaceutical Industries is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BridgeBio Pharma	6 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Teva Pharmaceutical Industries	15 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	3 Negative mention(s)	0 Very Negative mention(s)	Positive

Teva Pharmaceutical Industries has higher revenue and earnings than BridgeBio Pharma. BridgeBio Pharma is trading at a lower price-to-earnings ratio than Teva Pharmaceutical Industries, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BridgeBio Pharma	$502.08M	32.41	-$724.93M	-$3.74	N/A
Teva Pharmaceutical Industries	$17.26B	2.14	$1.41B	$1.33	24.17

Teva Pharmaceutical Industries has a net margin of 9.01% compared to BridgeBio Pharma's net margin of -124.42%. Teva Pharmaceutical Industries' return on equity of 43.53% beat BridgeBio Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BridgeBio Pharma	-124.42%	N/A	-65.81%
Teva Pharmaceutical Industries	9.01%	43.53%	8.19%

Summary

Teva Pharmaceutical Industries beats BridgeBio Pharma on 10 of the 16 factors compared between the two stocks.

How does BridgeBio Pharma compare to BeOne Medicines?

BridgeBio Pharma (NASDAQ:BBIO) and BeOne Medicines (NASDAQ:ONC) are both large-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, valuation, media sentiment, earnings, analyst recommendations, risk, institutional ownership and dividends.

99.9% of BridgeBio Pharma shares are held by institutional investors. Comparatively, 48.6% of BeOne Medicines shares are held by institutional investors. 14.2% of BridgeBio Pharma shares are held by insiders. Comparatively, 6.2% of BeOne Medicines shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

In the previous week, BridgeBio Pharma had 10 more articles in the media than BeOne Medicines. MarketBeat recorded 18 mentions for BridgeBio Pharma and 8 mentions for BeOne Medicines. BeOne Medicines' average media sentiment score of 0.77 beat BridgeBio Pharma's score of 0.70 indicating that BeOne Medicines is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BridgeBio Pharma	6 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
BeOne Medicines	3 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

BridgeBio Pharma presently has a consensus price target of $94.63, suggesting a potential upside of 13.90%. BeOne Medicines has a consensus price target of $391.38, suggesting a potential upside of 28.76%. Given BeOne Medicines' higher possible upside, analysts clearly believe BeOne Medicines is more favorable than BridgeBio Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BridgeBio Pharma	1 Sell rating(s)	2 Hold rating(s)	20 Buy rating(s)	0 Strong Buy rating(s)	2.83
BeOne Medicines	1 Sell rating(s)	2 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.80

BeOne Medicines has a net margin of 8.94% compared to BridgeBio Pharma's net margin of -124.42%. BeOne Medicines' return on equity of 12.06% beat BridgeBio Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BridgeBio Pharma	-124.42%	N/A	-65.81%
BeOne Medicines	8.94%	12.06%	6.69%

BridgeBio Pharma has a beta of 0.95, meaning that its share price is 5% less volatile than the broader market. Comparatively, BeOne Medicines has a beta of 0.49, meaning that its share price is 51% less volatile than the broader market.

BeOne Medicines has higher revenue and earnings than BridgeBio Pharma. BridgeBio Pharma is trading at a lower price-to-earnings ratio than BeOne Medicines, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BridgeBio Pharma	$502.08M	32.41	-$724.93M	-$3.74	N/A
BeOne Medicines	$5.34B	6.24	$286.93M	$4.47	68.00

Summary

BeOne Medicines beats BridgeBio Pharma on 10 of the 17 factors compared between the two stocks.

Get BridgeBio Pharma News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BBIO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BBIO vs. The Competition

Export

Metric	BridgeBio Pharma	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$16.82B	$6.08B	$7.05B	$12.61B
Dividend Yield	N/A	0.68%	2.68%	8.00%
P/E Ratio	-22.21	8.30	27.11	24.26
Price / Sales	32.41	21.99	587.92	117.88
Price / Cash	N/A	8.46	29.22	49.36
Price / Book	-7.71	4.22	10.75	6.29
Net Income	-$724.93M	$99.67M	$3.58B	$330.66M
7 Day Performance	6.64%	-4.13%	-2.06%	-1.32%
1 Month Performance	24.37%	7.79%	3.32%	-0.64%
1 Year Performance	74.21%	115.87%	26.35%	19.08%

BridgeBio Pharma Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BBIO BridgeBio Pharma	3.1076 of 5 stars	$83.08 -3.3%	$94.63 +13.9%	+78.8%	$16.82B	$502.08M	N/A	400	Analyst Forecast Insider Trade
ARGX argenex	4.3705 of 5 stars	$916.80 -2.4%	$1,034.56 +12.8%	+56.4%	$58.44B	$4.25B	40.82	1,863
TAK Takeda Pharmaceutical	1.5464 of 5 stars	$16.91 +0.8%	N/A	+12.4%	$53.37B	$28.32B	43.35	47,000
RVMD Revolution Medicines	1.9594 of 5 stars	$189.99 +0.4%	$142.33 -25.1%	+383.8%	$40.23B	$11.58M	N/A	250	Gap Down
TEVA Teva Pharmaceutical Industries	4.8057 of 5 stars	$35.29 +1.9%	$41.78 +18.4%	+96.2%	$39.83B	$17.26B	26.53	33,950	Positive News Analyst Downgrade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:BBIO) was last updated on 7/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

BridgeBio Pharma (BBIO) Competitors

BBIO vs. ARGX, TAK, RVMD, TEVA, and ONC

How does BridgeBio Pharma compare to argenex?

Summary

How does BridgeBio Pharma compare to Takeda Pharmaceutical?

Summary

How does BridgeBio Pharma compare to Revolution Medicines?

Summary

How does BridgeBio Pharma compare to Teva Pharmaceutical Industries?

Summary

How does BridgeBio Pharma compare to BeOne Medicines?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BBIO vs. The Competition

BridgeBio Pharma Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

BridgeBio Pharma (BBIO) Competitors

BBIO vs. ARGX, TAK, RVMD, TEVA, and ONC

How does BridgeBio Pharma compare to argenex?

Is BBIO or ARGX more profitable?

Which has more volatility and risk, BBIO or ARGX?

Which has stronger valuation & earnings, BBIO or ARGX?

Do analysts prefer BBIO or ARGX?

Do insiders and institutionals believe in BBIO or ARGX?

Does the media favor BBIO or ARGX?

Summary

How does BridgeBio Pharma compare to Takeda Pharmaceutical?

Is BBIO or TAK more profitable?

Which has more volatility & risk, BBIO or TAK?

Do analysts prefer BBIO or TAK?

Do insiders & institutionals hold more shares of BBIO or TAK?

Which has stronger earnings and valuation, BBIO or TAK?

Does the media prefer BBIO or TAK?

Summary

How does BridgeBio Pharma compare to Revolution Medicines?

Which has more risk and volatility, BBIO or RVMD?

Do institutionals and insiders hold more shares of BBIO or RVMD?

Which has better valuation and earnings, BBIO or RVMD?

Do analysts prefer BBIO or RVMD?

Does the media prefer BBIO or RVMD?

Is BBIO or RVMD more profitable?

Summary

How does BridgeBio Pharma compare to Teva Pharmaceutical Industries?

Which has more risk & volatility, BBIO or TEVA?

Do analysts rate BBIO or TEVA?

Do institutionals & insiders hold more shares of BBIO or TEVA?

Does the media prefer BBIO or TEVA?

Which has higher earnings & valuation, BBIO or TEVA?

Is BBIO or TEVA more profitable?

Summary

How does BridgeBio Pharma compare to BeOne Medicines?

Do insiders & institutionals hold more shares of BBIO or ONC?

Does the media prefer BBIO or ONC?

Do analysts rate BBIO or ONC?

Is BBIO or ONC more profitable?

Which has more volatility & risk, BBIO or ONC?

Which has preferable valuation & earnings, BBIO or ONC?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BBIO vs. The Competition

BridgeBio Pharma Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools